MONTE ROSA THERAPEUTICS INC (GLUE)
Health Care · Protein degradation therapeutics / targeted protein degradation · NASDAQ
Monte Rosa Therapeutics develops molecular glue degraders—a novel class of protein degradation drugs targeting historically undruggable proteins through its proprietary QuEEN discovery platform.
What MONTE ROSA THERAPEUTICS INC does
Monte Rosa Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing molecular glue degraders (MGDs), a class of small-molecule therapeutics designed to degrade disease-causing proteins. The company leverages its proprietary QuEEN discovery engine and proteomics capabilities to identify and target proteins previously considered undruggable or inadequately addressed by conventional approaches. Monte Rosa has a pipeline of internally developed MGD candidates targeting GSPT1 (MRT-2359), NEK7 (MRT-8102), CDK2/CCNE1, and has partnered VAV1-directed programs (MRT-6160) with Novartis and Roche.
Themes: ["Protein degradation / molecular glue degraders","Undruggable protein targets","Oncology","Drug discovery platform","Precision medicine"]
Fundamentals
- Price$24.52 as of 2026-07-09 close
- Market cap$2.1B as of 2026-07-10
- 1-year return+375.5% as of 2026-07-09 close
- Net margin-302.7% as of 2026-07-10
- ROE-41.0% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-73.1% as of 2026-07-10
- Beta1.48 as of 2026-07-10
Key risks (from latest filing)
["Heavy dependence on strategic collaborations (Novartis and Roche partnerships) for revenue and product development success; significant revenue decline (-73% YoY in 2026) indicates substantial reliance on milestone payments that may be unpredictable.","Clinical development risk: multiple programs still in preclinical or early-stage clinical phases with uncertain timelines for IND applications, regulatory approval, and commercialization success.","Substantial operating losses and negative margins (-302.69% net margin) with high R&D spending; company will require continued funding to complete development and commercialization of product candidates."]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.